Business Context and Reporting Period
This Form 8-K Current Report was filed by Viking Therapeutics, Inc. on April 8, 2016. The filing discloses the entry into a material definitive agreement regarding an underwritten public offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Offering Size: 7,500,000 shares of Common Stock and warrants to purchase 7,500,000 shares.
- Public Offering Price: $1.25 per share of Common Stock and related Warrant.
- Expected Net Proceeds: Approximately $8.1 million (excluding over-allotment).
- Warrant Terms: Exercise price of $1.50 per share; immediately exercisable; expire five years from issuance.
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to 1,125,000 additional shares and/or warrants at $1.24 per share and $0.01 per warrant.
- Expected Closing Date: On or about April 13, 2016.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement with Maxim Group LLC. This agreement facilitates the capital raise described above. Additionally, the Company agreed to pay underwriters' expenses up to a maximum of $75,000. Directors, executive officers, and certain principal stockholders have entered into lock-up agreements prohibiting the sale of securities for 90 days following April 8, 2016.
Outlook, Risks, and Contingencies
The closing of the offering is subject to the satisfaction of customary closing conditions. The filing includes forward-looking statements regarding the anticipated closing and proceeds, which are subject to risks including the Company's ability to satisfy closing conditions and general market conditions. The Company explicitly states it does not intend to revise or update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds once the transaction completes.
- Confirm whether the underwriters exercise the over-allotment option to purchase additional shares.
- Review the full Underwriting Agreement (Exhibit 1.1) and Warrant Agreement (Exhibit 4.1) for specific covenants and representations.
- Monitor the trading of the new warrants under ticker symbol "VKTXW" on the Nasdaq Capital Market.